Highly purified eicosapentaenoic acid ameliorates cardiac injury and adipose tissue inflammation in a rat model of metabolic syndrome

Obesity Science and Practice

Volumn 2, Issue 3, 2016, Pages 318-329

  Ito, S ^a   Sano, Y ^a   Nagasawa, K ^a   Matsuura, N ^a   Yamada, Y ^a   Uchinaka, A ^a   Murohara, T ^a   Nagata, K ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adiponectin; eicosapentaenoic acid; inflammation; metabolic syndrome

Indexed keywords

ADIPONECTIN; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPID; OMEGA 3 FATTY ACID; SYNAPTOTAGMIN I;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CONTROLLED STUDY; DAHL SALT SENSITIVE RAT; DIASTOLIC DYSFUNCTION; DOWN REGULATION; ECHOCARDIOGRAPHY; FOOD INTAKE; GLUCOSE METABOLISM; HEART CATHETERIZATION; HEART INJURY; HEART MUSCLE FIBROSIS; HEART TISSUE; HISTOPATHOLOGY; HOMOZYGOSITY; HYPERTENSION; HYPERTROPHY; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INSULIN RESISTANCE; INTRAPERITONEAL FAT; LIPID METABOLISM; MALE; METABOLIC SYNDROME X; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE AGGREGATION; UPREGULATION; ZUCKER RAT;

EID: 85020255394     PISSN: None     EISSN: 20552238     Source Type: Journal    
DOI: 10.1002/osp4.50     Document Type: Article

References (49)

1. Romeo GR, Lee J, Shoelson SE. Metabolic syndrome, insulin resistance, and roles of inflammation – mechanisms and therapeutic targets. Arterioscler Thromb Vasc Biol 2012; 32: 1771–1776.
2. Matsuzawa Y. Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 2006; 3: 35–42.
3. Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 2012; 18: 363–374.
4. Hu FB, Bronner L, Willett WC, et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. Jama 2002; 287: 1815–1821.
5. Calder PC. n-3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored. Clin Sci (Lond) 2004; 107: 1–11.
6. Saravanan P, Davidson NC, Schmidt EB, Calder PC. Cardiovascular effects of marine omega-3 fatty acids. Lancet 2010; 376: 540–550.
7. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007; 369: 1090–1098.
8. Itoh M, Suganami T, Satoh N, et al. Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. Arterioscler Thromb Vasc Biol 2007; 27: 1918–1925.
9. Yamada H, Yoshida M, Nakano Y, et al. In vivo and in vitro inhibition of monocyte adhesion to endothelial cells and endothelial adhesion molecules by eicosapentaenoic acid. Arterioscler Thromb Vasc Biol 2008; 28: 2173–2179.
10. Simopoulos AP. Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation: nutritional implications for chronic diseases. Biomed Pharmacother 2006; 60: 502–507.
11. fa rat. Nutr Diabetes 2011; 1: e1.
12. Kokura S, Nakagawa S, Hara T, et al. Enhancement of lipid peroxidation and of the antitumor effect of hyperthermia upon combination with oral eicosapentaenoic acid. Cancer Lett 2002; 185: 139–144.
13. Hamazaki T, Urakaze M, Makuta M, et al. Intake of different eicosapentaenoic acid-containing lipids and fatty acid pattern of plasma lipids in the rats. Lipids 1987; 22: 994–998.
14. Takeshita Y, Watanabe S, Hattori T, et al. Blockade of glucocorticoid receptors with RU486 attenuates cardiac damage and adipose tissue inflammation in a rat model of metabolic syndrome. Hypertens Res 2015; 38: 741–750.
15. Nagata K, Somura F, Obata K, et al. AT1 receptor blockade reduces cardiac calcineurin activity in hypertensive rats. Hypertension 2002; 40: 168–174.
16. Matsuura N, Nagasawa K, Minagawa Y, et al. Restraint stress exacerbates cardiac and adipose tissue pathology via beta-adrenergic signaling in rats with metabolic syndrome. Am J Physiol Heart Circ Physiol 2015; 308: H1275–1286.
17. Hattori T, Murase T, Takatsu M, et al. Dietary salt restriction improves cardiac and adipose tissue pathology independently of obesity in a rat model of metabolic syndrome. J Am Heart Assoc 2014; 3: e001312.
18. Kato MF, Shibata R, Obata K, et al. Pioglitazone attenuates cardiac hypertrophy in rats with salt-sensitive hypertension: role of activation of AMP-activated protein kinase and inhibition of Akt. J Hypertens 2008; 26: 1669–1676.
19. Miyachi M, Yazawa H, Furukawa M, et al. Exercise training alters left ventricular geometry and attenuates heart failure in Dahl salt-sensitive hypertensive rats. Hypertension 2009; 53: 701–707.
20. Matsuura N, Asano C, Nagasawa K, et al. Effects of pioglitazone on cardiac and adipose tissue pathology in rats with metabolic syndrome. Int J Cardiol 2015; 179: 360–369.
21. Nagasawa K, Matsuura N, Takeshita Y, et al. Attenuation of cold stress-induced exacerbation of cardiac and adipose tissue pathology and metabolic disorders in a rat model of metabolic syndrome by the glucocorticoid receptor antagonist RU486. Nutr Diabetes 2016; 6: e207.
22. Nagata K, Obata K, Xu J, et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 2006; 47: 656–664.
23. Takatsu M, Hattori T, Murase T, et al. Comparison of the effects of cilnidipine and amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats. J Hypertens 2012; 30: 1845–1855.
24. Elmarakby AA, Loomis ED, Pollock JS, Pollock DM. NADPH oxidase inhibition attenuates oxidative stress but not hypertension produced by chronic ET-1. Hypertension 2005; 45: 283–287.
25. Miyata K, Rahman M, Shokoji T, et al. Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol 2005; 16: 2906–2912.
26. Sakata Y, Yamamoto K, Mano T, et al. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of angiotensin-converting enzyme inhibitor. Circulation 2004; 109: 2143–2149.
27. fa rats as a new animal model of metabolic syndrome. Hypertension 2012; 59: 694–704.
28. Yamada T, Nagata K, Cheng XW, et al. Long-term administration of nifedipine attenuates cardiac remodeling and diastolic heart failure in hypertensive rats. Eur J Pharmacol 2009; 615: 163–170.
29. fa rats: a new animal model of metabolic syndrome. Hypertens Res 2012; 35: 186–193.
30. Takatsu M, Nakashima C, Takahashi K, et al. Calorie restriction attenuates cardiac remodeling and diastolic dysfunction in a rat model of metabolic syndrome. Hypertension 2013; 62: 957–965.
31. Xu J, Nagata K, Obata K, et al. Nicorandil promotes myocardial capillary and arteriolar growth in the failing heart of Dahl salt-sensitive hypertensive rats. Hypertension 2005; 46: 719–724.
32. Rousseau D, Helies-Toussaint C, Moreau D, Raederstorff D, Grynberg A. Dietary n-3 PUFAs affect the blood pressure rise and cardiac impairments in a hyperinsulinemia rat model in vivo. Am J Physiol Heart Circ Physiol 2003; 285: H1294–1302.
33. Chen J, Shearer GC, Chen Q, et al. Omega-3 fatty acids prevent pressure overload-induced cardiac fibrosis through activation of cyclic GMP/protein kinase G signaling in cardiac fibroblasts. Circulation 2011; 123: 584–593.
34. Hwang IS, Ho H, Hoffman BB, Reaven GM. Fructose-induced insulin resistance and hypertension in rats. Hypertension 1987; 10: 512–516.
35. Chen C, Yu X, Shao S. Effects of omega-3 fatty acid supplementation on glucose control and lipid levels in type 2 diabetes: a meta-analysis. PLoS One 2015; 10: e0139565.
36. Reis CE, Landim KC, Nunes AC, Dullius J. Safety in the hypertriglyceridemia treatment with N-3 polyunsaturated fatty acids on glucose metabolism in subjects with type 2 diabetes mellitus. Nutr Hosp 2014; 31: 570–576.
37. Szkudelski T. Streptozotocin-nicotinamide-induced diabetes in the rat. Characteristics of the experimental model. Exp Biol Med (Maywood) 2012; 237: 481–490.
38. Nugent DA, Smith DM, Jones HB. A review of islet of Langerhans degeneration in rodent models of type 2 diabetes. Toxicol Pathol 2008; 36: 529–551.
39. Hartweg J, Perera R, Montori V, et al. Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008 Cd003205.
40. Crochemore IC, Souza AF, de Souza AC, Rosado EL. Omega-3 polyunsaturated fatty acid supplementation does not influence body composition, insulin resistance, and lipemia in women with type 2 diabetes and obesity. Nutr Clin Pract 2012; 27: 553–560.
41. Kalupahana NS, Claycombe KJ, Moustaid-Moussa N. (n-3) Fatty acids alleviate adipose tissue inflammation and insulin resistance: mechanistic insights. Adv Nutr 2011; 2: 304–316.
42. Sato A, Kawano H, Notsu T, et al. Antiobesity effect of eicosapentaenoic acid in high-fat/high-sucrose diet-induced obesity: importance of hepatic lipogenesis. Diabetes 2010; 59: 2495–2504.
43. Flachs P, Mohamed-Ali V, Horakova O, et al. Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet. Diabetologia 2006; 49: 394–397.
44. Arita M, Yoshida M, Hong S, et al. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A 2005; 102: 7671–7676.
45. Salminen A, Hyttinen JM, Kaarniranta K. AMP-activated protein kinase inhibits NF-kappaB signaling and inflammation: impact on healthspan and lifespan. J Mol Med (Berl) 2011; 89: 667–676.
46. Xue B, Yang Z, Wang X, Shi H. Omega-3 polyunsaturated fatty acids antagonize macrophage inflammation via activation of AMPK/SIRT1 pathway. PLoS One 2012; 7: e45990.
47. Dyck JR. The ischemic heart: starving to stimulate the adiponectin-AMPK signaling axis. Circulation 2007; 116: 2779–2781.
48. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409–2415.
49. Wang S, Zhang M, Liang B, et al. AMPKalpha2 deletion causes aberrant expression and activation of NAD(P)H oxidase and consequent endothelial dysfunction in vivo: role of 26S proteasomes. Circ Res 2010; 106: 1117–1128.